Elevance Health, Inc. (NYSE:ELV – Free Report) – Stock analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Elevance Health in a research report issued on Thursday, January 30th. Zacks Research analyst K. Dey now expects that the company will post earnings of $9.85 per share for the quarter, down from their previous estimate of $10.35. The consensus estimate for Elevance Health’s current full-year earnings is $34.07 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $5.31 EPS, FY2025 earnings at $34.16 EPS, Q1 2026 earnings at $12.30 EPS, Q2 2026 earnings at $11.67 EPS, Q3 2026 earnings at $10.23 EPS, Q4 2026 earnings at $6.10 EPS and FY2026 earnings at $40.30 EPS.
Other equities analysts have also recently issued reports about the company. Argus reiterated a “hold” rating and issued a $405.40 price objective on shares of Elevance Health in a report on Wednesday, January 29th. Mizuho cut their target price on Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Truist Financial decreased their price target on shares of Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $485.00 price objective on shares of Elevance Health in a research note on Friday, January 24th. Finally, TD Cowen reduced their target price on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $517.03.
Elevance Health Stock Down 0.7 %
Shares of NYSE:ELV opened at $402.29 on Monday. The firm has a market capitalization of $93.30 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 1.19 and a beta of 0.83. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health has a 52-week low of $362.21 and a 52-week high of $567.26. The firm has a fifty day moving average of $386.45 and a 200 day moving average of $456.00.
Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%.
Institutional Trading of Elevance Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELV. Centaurus Financial Inc. boosted its stake in shares of Elevance Health by 66.9% during the 2nd quarter. Centaurus Financial Inc. now owns 918 shares of the company’s stock valued at $498,000 after purchasing an additional 368 shares in the last quarter. Czech National Bank lifted its holdings in Elevance Health by 6.7% in the third quarter. Czech National Bank now owns 47,237 shares of the company’s stock worth $24,563,000 after buying an additional 2,947 shares during the period. Handelsbanken Fonder AB boosted its position in Elevance Health by 4.1% during the 3rd quarter. Handelsbanken Fonder AB now owns 75,320 shares of the company’s stock valued at $39,166,000 after acquiring an additional 2,987 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Elevance Health by 19.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,098 shares of the company’s stock worth $1,611,000 after acquiring an additional 502 shares during the period. Finally, Chemistry Wealth Management LLC raised its position in shares of Elevance Health by 4.0% in the 3rd quarter. Chemistry Wealth Management LLC now owns 6,793 shares of the company’s stock worth $3,533,000 after acquiring an additional 261 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Elevance Health Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend is Monday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s dividend payout ratio is currently 25.46%.
About Elevance Health
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
See Also
- Five stocks we like better than Elevance Health
- The 3 Best Blue-Chip Stocks to Buy Now
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What is the FTSE 100 index?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Best Stocks Under $5.00
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.